Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp

422Citations
Citations of this article
706Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.

Cite

CITATION STYLE

APA

Alfarouk, K. O., Stock, C. M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., … Rauch, C. (2015, July 15). Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp. Cancer Cell International. BioMed Central Ltd. https://doi.org/10.1186/s12935-015-0221-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free